Aaron Milstone, MD
Pulmonary Disease · Franklin, TNNPI 1134211550
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $347,966 of the $482,423 with a category attached, or 72.1%. 48 manufacturers reported payments, led by Boehringer Ingelheim at 25.9% of the total. Reporting peaked in 2019 at $210,662 and has fallen 90.8% since, to $19,376 in 2025. Among pulmonary disease clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 757 payments — averaging $637.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$125K
- GSK$110K
- Mylan Specialty L.p.$97K
- Genentech USA, Inc.$51K
- Insmed, Inc.$38K
- Mylan Inc.$21K
- plus $40K from 42 others
Across 1,026 payments — averaging $1909.62 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim$508K
- AstraZeneca$293K
- Insmed, Inc.$271K
- United Therapeutics Corporation$221K
- GSK$172K
- Sanofi US Services Inc.$130K
- plus $364K from 10 others
What the payments were for
- Consulting fees$54,88111%
- Speaking & faculty fees$347,96672%
- Travel & lodging$62,27413%
- Food & beverage$16,3423%
- Education$9610%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Yupelri$113,789
- OFEV$55,217
- TRELEGY ELLIPTA$53,867
- Xofluza$50,316
- Arikayce$26,553
- Ohtuvayre$11,518
- ANORO ELLIPTA$7,321
- Prolastin-C Liquid$3,439
- PURIFIED CORTROPHIN GEL$1,913
- XOLAIR$1,444
- Prolastin-C$1,420
- SPIRIVA$1,321
- STIOLTO RESPIMAT$1,300
- BREZTRI$723
- BREZTRI AEROSPHERE$361
- Inspire$133
- AIRSUPRA$124
- Dayvigo$121
- Wakix$119
- QUVIVIQ$115
How this compares
$482,423 in reported general payments places this provider in the 95th percentile of 339 pulmonary disease providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 367 | $290,763 |
| GlassiaAlpha-1-Proteinase Inhibitor | 14 | $207,230 |
| ZemairaAlpha-1-Proteinase Inhibitor | 13 | $167,917 |
| Aralast NpAlpha-1-Proteinase Inhibitor | 13 | $137,180 |
| Breo ElliptaFluticasone/Vilanterol | 216 | $113,493 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 13 | $89,565 |
| Ambrisentan | 13 | $65,975 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 67 | $63,658 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 95 | $51,245 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 67 | $44,461 |
| Spiriva RespimatTiotropium Bromide | 42 | $28,208 |
| EliquisApixaban | 27 | $21,691 |
| Spiriva HandihalerTiotropium Bromide | 25 | $15,634 |
| XareltoRivaroxaban | 21 | $13,365 |
| SymbicortBudesonide/Formoterol Fumarate | 29 | $12,139 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta | $110,383 | $460,864694 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Glassia | $106 | $207,23014 claims |
| CSL BehringZemaira | $1,963 | $167,91713 claims |
| Grifols USA, LLCProlastin C | $5,012 | $89,56513 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat, Combivent Respimat | $124,948 | $84,484134 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $7,956 | $75,79696 claims |
| PfizerEliquis | $21 | $21,69127 claims |
| Johnson & JohnsonXarelto | $26 | $13,36521 claims |
| MerckDulera, Belsomra | $35 | $12,81434 claims |
| Mylan Inc.Wixela Inhub | $21,368 | $2,41016 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 339 pulmonary disease providers in Tennessee.
Other pulmonary disease in Franklin
- Lisa LancasterNashville$519K
- Krishnendu BhadraChattanooga$494K
- Otis RickmanNashville$392K
- Michael CzarneckiChattanooga$348K
- Susan GarwoodNashville$343K
- Girendra HoskereBristol$285K
- Carlos BaleeiroChattanooga$265K
- Joao DeandradeNashville$245K
- John SwisherKnoxville$234K
- Anna HemnesNashville$183K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.